Understanding the incretin effect

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 934-935

  Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; INSULIN; PLACEBO; VILDAGLIPTIN;

DRUG TARGETING; EDITORIAL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; COMPREHENSION; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; NITRILES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79953851412     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2011-0329     Document Type: Editorial

References (12)

1. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
2. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
3. Seino Y, Fukushima M, Yabe D 2010 GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diab Invest 1:8-23
4. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, CreutzfeldtW1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307 (Pubitemid 23037285)
5. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119 (Pubitemid 34985287)
6. Vardarli I, Nauck MA, Köthe LD, Deacon CF, Holst JJ, Schweizer A, Foley JE 2011 Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:945-954
7. Elrick H, Stimmler L, Hlad Jr. CJ, Arai Y 1964 Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082
8. Mclntyre N, Holdsworth CD, Turner DS 1964 New interpretation of oral glucose tolerance. Lancet 2:20-21
9. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, CreutzfeldtW1986 Incretin effect of increasing glucose loads inman calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498 (Pubitemid 16035703)
10. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W 1986 Reduction incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52 (Pubitemid 16162741)
11. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T 2007 Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state? Diabetes 56:1951-1959 (Pubitemid 47195814)
12. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T 2007 Inappropriate suppression of glucagons during OGTT but not during isoglycemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50:797-805 (Pubitemid 46355821)